Molecular Design of Unimolecular Tetra-Receptor Agonists.
This study reports the first-in-class design of unimolecular "tetra-agonists" — single peptide molecules engineered to simultaneously activate four metabolically relevant receptors: GLP-1R, GIPR, GcgR (all class B GPCRs), and Y2R (a class A GPCR). Prior work had yielded dual and triple agonists exploiting sequence homology among class B GPCR ligands, but incorporating Y2R agonism was considered a major challenge due to the structural and sequence divergence between class A and class B GPCRs. The researchers used rational chimeric peptide design to overcome these topological constraints, producing high-potency tetra-agonists. They further showed that lipidation of the scaffold was well tolerated, potentially improving therapeutic viability. The study also explored biased agonism at GLP-1R, demonstrating that cAMP signaling could be selectively amplified while minimizing β-arrestin recruitment — a mechanism that may reduce receptor desensitization. A tunable framework for modulating β-arrestin engagement without compromising cAMP potency is also described. Limitations include that all experiments appear to be conducted in vitro (cell-based receptor activation and signaling assays), with no animal or human efficacy data reported. The work is primarily a molecular pharmacology and peptide chemistry study establishing proof-of-concept at the receptor level.
Why this grade: All reported findings are derived from cell-based receptor binding and signaling assays (cAMP, β-arrestin recruitment); no animal models or human subjects are described in the abstract.
Peptide hormone-receptor interactions serve as critical regulators of metabolic homeostasis, a paradigm exemplified by the clinical efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists. Building upon this framework, strategic design has yielded unimolecular dual and triple agonists targeting GLP-1R, glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GcgR), leveraging the sequence homology within the cognate native ligands of the class B G protein-coupled receptor (GPCR) family. However, the integration of Y2 receptor (Y2R) agonism─engaged by peptide YY (PYY) and belonging to the structurally divergent class A GPCR family─has remained an unaddressed challenge due to the topological and sequence disparities between these receptor classes. Y2R activation plays a pivotal role in appetite suppression, potentiating the metabolic benefits conferred by GLP-1R, GIPR, and GcgR agonism. Here, we report first-in-class, unprecedented tetra-agonists with high potency at GLP-1R, GIPR, GcgR, and Y2R. The chimeric peptides overcome the intrinsic sequence constraints imposed by class A and class B GPCR divergence, demonstrating the feasibility of rationally designed agonism mediated by single agents across receptor families. Lipidation of this template is well tolerated enhancing the promise of therapeutic viability. Furthermore, we show that biased agonism at GLP-1R selectively boosts cyclic AMP (cAMP) signaling while minimizing β-arrestin recruitment, thereby decoupling receptor desensitization from metabolic efficacy. Additionally, we introduce a tunable framework to modulate β-arrestin engagement without compromising cAMP potency, providing insight into the fine-tuning of GPCR-mediated signaling for next-generation peptide therapeutics.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.